Looks like you’re on the UK site. Choose another location to see content specific to your location
Janssen to be bolstered by Alios BioPharma takeover
Janssen has announced that its parent company Johnson and Johnson has agreed to purchase Alios BioPharma, a move that will strengthen Janssen's portfolio.
The privately-held clinical-stage biopharmaceutical company – which focuses on developing therapies for viral diseases – is being purchased for around $1.75 billion (1.1 billion pounds), with the transaction expected to close during the fourth quarter of 2014.
As part of the deal, Janssen will gain access to Alios BioPharma's portfolio of potential therapeutics for viral infections, including the promising compound AL-8176, which is currently in phase II studies for the treatment of infants with respiratory syncytial virus (RSV).
This aligns with Janssen's existing research priorities, as RSV is the leading cause of acute lower respiratory infection in children under the age of five, and the last of the major paediatric diseases with no available preventive therapy.
Dr Johan Van Hoof, global head of infectious diseases and vaccines at Janssen, said: "This acquisition will allow us to combine their innovative compounds with our vast experience in viral diseases to deliver novel medicines and treatment options for patients worldwide."
Last month, the company announced that it has fast-tracked the development of a promising new combination vaccine regimen against Ebola, with the aim of tackling the current outbreak in Africa.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard